文献速递浆细胞疾病造血干细胞移植与细胞治疗

多发性骨髓瘤患者接受G-CSF或G-CSF联合普乐沙福动员移植物进行自体造血干细胞移植的临床结局

Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts.
PubMed 文献 · Am J Hematol · 2019-12-11

该回顾性分析纳入469例单用G-CSF动员和141例G-CSF联合普乐沙福动员的多发性骨髓瘤自体移植患者,比较第30天绝对淋巴细胞计数(ALC30)、无进展生存(PFS)和总生存(OS)。

核心结论

  • 在G-CSF动员失败后改用普乐沙福的患者中,淋巴细胞恢复和PFS与单用G-CSF动员者无显著差异,但OS显著更短。

研究设计与样本

  • 回顾性分析纳入469例单用G-CSF动员和141例G-CSF联合普乐沙福动员的多发性骨髓瘤自体移植患者。
  • 仅当首次计划采集日外周血CD34+计数<20/μL时才使用普乐沙福。

主要发现

  • OS中位随访时间在G组为2.53年(95%CI 2.13-2.99),G+P组为1.59年(95%CI 1.17-2.02)。

临床怎么用

  • 对于G-CSF动员不佳的多发性骨髓瘤患者,加用普乐沙福虽不影响淋巴细胞恢复和PFS,但需关注OS可能更差的信号。

局限性

  • 回顾性设计,普乐沙福组仅为动员失败者,存在选择偏倚。
  • 两组随访时间不同,OS结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Impact of Plerixafor (P) mobilized stem cells on immune reconstitution, such as absolute lymphocyte count at day 30 (ALC30), and on long-term outcomes of Multiple Myeloma (MM) patients undergoing autologous stem cell transplant (ASCT) has not been well established. We evaluated total of 469 patients mobilized with G-CSF (G) alone, and 141 patients mobilized with G-CSF plus plerixafor (G+ P). Patients only received plerixafor if they had peripheral blood CD34+ blood count <20/μL on first planned day of collection. Primary endpoint, ALC30, was 1.3 K/μL (range, 0.1-4.5) and 1.2 K/μL (range, 0.1-5.1) for G and G + P, respectively (P =. 61). The median PFS was 2.5 years (95% CI, 2.1-3.2) and 2.8 years (95% CI, 2.0-3.3) for G and G + P, respectively (HR: 1.13; 95% CI, 0.84-1.50; P = .42). The median OS was 6.1 years (95% CI, 4.6-NR) for G group compared to 3.7 years (95% CI, 3.2-NR) for the G + P group (HR: 1.64; 95% CI, 1.12-2.40; P = .01). The median follow-up time for OS was 2.53 years (95% CI, 2.13-2.99) and 1.59 years (95% CI, 1.17-2.02) for G and G+ P group, respectively. In this large retrospective analysis of MM patients mobilized with G-CSF vs G-CSF + P, there was no significant difference in lymphocyte recovery or PFS. There was an overall survival difference in patients who were poor mobilizers and could not be mobilized with G-CSF alone.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Shah H, Kim S, Singh P, et al. Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts. Am J Hematol. 2019. PMID: 31691333. doi:10.1002/ajh.25672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。